8-K: Ovid Therapeutics Announces Business Updates and Full Year 2023 Financial Results

Ovid Therapeutics reports progress in clinical trials, anticipates key milestones, and provides financial results for 2023, highlighting a cash runway into the first half of 2026.

Summary

• Ovid Therapeutics has announced its business updates and financial results for the fourth quarter and full year 2023.
• The company completed enrollment in two pivotal Phase 3 clinical trials for soticlestat, with Takeda expecting topline data by or before September 2024.
• OV888 (GV101) is progressing in a Phase 1 trial, with a higher dose cohort added and no serious adverse events reported.
• A Phase 2 study of OV888 (GV101) is expected to begin in the second half of 2024.
• The Phase 1 study for OV329 is ongoing, with data expected in the second half of 2024.
• Ovid's cash, cash equivalents, and marketable securities totaled $105.8 million as of December 31, 2023, which is expected to support operations into the first half of 2026.
• Ovid anticipates five clinical and regulatory milestones from its pipeline this year.
• The company sold a 13% interest in soticlestat's potential future milestone payments and royalties to Ligand Pharmaceuticals for $30 million in October 2023, retaining 87% of its interest.
• Ovid's revenue for 2023 was $0.4 million, compared to $1.5 million in 2022.
• Research and development expenses were $28.6 million for the full year 2023, compared to $24.6 million in 2022.
• The company reported a net loss of $52.3 million for the year ended December 31, 2023, compared to a net loss of $54.2 million in 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a solid cash position, but also acknowledges financial losses and risks inherent in drug development. The sentiment is cautiously optimistic.

Positives

• The company has completed enrollment in two pivotal Phase 3 trials for soticlestat.
• OV888 (GV101) is progressing well in its Phase 1 trial, with no serious adverse events reported.
• Ovid has a strong cash position of $105.8 million, expected to fund operations into the first half of 2026.
• The company anticipates multiple clinical and regulatory milestones in 2024.
• Ovid retains a significant financial interest in soticlestat, with potential for substantial milestone payments and royalties.
• The company secured $30 million in non-dilutive capital from Ligand Pharmaceuticals.

Negatives

• Ovid's revenue decreased to $0.4 million in 2023 from $1.5 million in 2022.
• The company reported a net loss of $52.3 million for the year ended December 31, 2023.
• Research and development expenses increased to $28.6 million in 2023 from $24.6 million in 2022.
• General and administrative expenses were $31.1 million for the year ended December 31, 2023.

Risks

• The success of clinical trials for soticlestat and other pipeline candidates is not guaranteed.
• Regulatory approvals for Ovid's drug candidates are subject to uncertainty.
• The company's ability to achieve its financial objectives is subject to various risks.
• Ovid may not be able to realize the intended benefits of its technology or business strategy.
• There are risks related to identifying business development targets or strategic partners.
• The company's future revenue is dependent on the success of its pipeline and potential collaborations.

Future Outlook

Ovid anticipates five clinical and regulatory milestones from its pipeline in 2024, and Takeda is expected to release results from two pivotal Phase 3 studies for soticlestat. The company's cash runway is expected to support operations into the first half of 2026. Ovid is also exploring out-licensing opportunities and potential collaborations.

Management Comments

• Dr. Jeremy Levin, Chairman and CEO of Ovid, stated that the company is progressing well and anticipates five clinical and regulatory milestones this year.
• Dr. Levin mentioned that the ROCK2 collaboration with Graviton Bioscience is producing results faster than expected.
• Dr. Levin noted that if the soticlestat trials are successful, a new medicine will be available to LGS and DS patients in 2025, and Ovid will be eligible for milestone payments and royalties.

Industry Context

Ovid's focus on rare epilepsies and brain conditions aligns with the growing interest in developing treatments for neurological disorders. The company's pipeline, including soticlestat, OV888, and OV329, targets specific mechanisms of action relevant to these conditions. The collaboration with Takeda and Graviton Bioscience reflects a trend of partnerships in the biotech industry to advance drug development.

Comparison to Industry Standards

• Ovid's R&D spending of $28.6 million for the year is typical for a clinical-stage biotech company, but it is important to compare this to companies with similar pipelines and stages of development.
• The cash runway into the first half of 2026 is a positive sign, but it is important to compare this to the burn rate of other companies in the sector.
• The potential milestone payments and royalties from soticlestat are significant, but the actual realization of these payments depends on the success of Takeda's commercialization efforts.
• Companies like BioMarin Pharmaceutical and Ultragenyx Pharmaceutical are also focused on rare diseases and have similar development timelines, but they have different financial profiles and product portfolios.
• The collaboration with Takeda is similar to other partnerships in the industry, where larger pharmaceutical companies collaborate with smaller biotechs to develop and commercialize new drugs.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the company's cash runway.
• Employees may be motivated by the company's pipeline advancements and future prospects.
• Patients with rare epilepsies and brain conditions may benefit from the potential development of new treatments.
• Suppliers and creditors may be reassured by the company's financial stability and future plans.

Next Steps

• Ovid will continue to advance its clinical pipeline, including OV888 and OV329.
• The company expects to initiate a Phase 2 study of OV888 in the second half of 2024.
• Ovid anticipates data from the Phase 1 study of OV329 in late 2024.
• Takeda is expected to release topline data from the soticlestat Phase 3 trials by or before September 2024.
• Ovid will explore out-licensing opportunities and potential collaborations for its KCC2 portfolio.

Key Dates

Keywords

Ovid Therapeutics, soticlestat, OV888, GV101, OV329, OV350, Lennox-Gastaut syndrome, Dravet syndrome, epilepsy, clinical trials, Phase 3, Phase 1, Phase 2, ROCK2 inhibitor, GABA-AT inhibitor, KCC2 activator, biopharmaceutical, neurological conditions, milestone payments, royalties